Comparative Pharmacology
Head-to-head clinical analysis: WYAMYCIN E versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WYAMYCIN E versus ZMAX.
WYAMYCIN E vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic